CBR1 is correlated with doxorubicin resistance in human gastrointestinal cancer, and the efficacy of doxorubicin can be improved by inhibiting CBR1 in breast cancer treatment (Jo et al., 2017; Matsunaga et al., 2015). Here, CBR1 is linked to breast carcinoma.